These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7362699)

  • 1. Therapeutic effects of ML-236B in primary hypercholesterolemia.
    Yamamoto A; Sudo H; Endo A
    Atherosclerosis; 1980 Mar; 35(3):259-66. PubMed ID: 7362699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking 3-hydroxy-3-methylglutaryl coenzyme A reductase with ML-236B enhances the plasma cortisol response to adrenocorticotropin in patients with hypercholesterolemia.
    Yamaguchi K; Nakamura N; Uzawa H
    J Clin Endocrinol Metab; 1984 May; 58(5):786-9. PubMed ID: 6323515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
    Mabuchi H; Sakai T; Sakai Y; Yoshimura A; Watanabe A; Wakasugi T; Koizumi J; Takeda R
    N Engl J Med; 1983 Mar; 308(11):609-13. PubMed ID: 6828091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.
    Mabuchi H; Haba T; Tatami R; Miyamoto S; Sakai Y; Wakasugi T; Watanabe A; Koizumi J; Takeda R
    N Engl J Med; 1981 Aug; 305(9):478-82. PubMed ID: 7254297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ML-236b (compactin) on sterol synthesis and low density lipoprotein receptor activities in fibroblasts of patients with homozygous familial hypercholesterolemia.
    Haba T; Mabuchi H; Yoshimura A; Watanabe A; Wakasugi T; Tatami R; Ueda K; Ueda R; Kametani T; Koizumi J; Miyamoto S; Takeda R; Takeshita H
    J Clin Invest; 1981 May; 67(5):1532-40. PubMed ID: 7229037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of probucol on homozygous cases of familial hypercholesterolemia.
    Yamamoto A; Matsuzawa Y; Kishino B; Hayashi R; Hirobe K; Kikkawa T
    Atherosclerosis; 1983 Aug; 48(2):157-66. PubMed ID: 6615580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II.
    JAMA; 1986 Nov; 256(20):2829-34. PubMed ID: 3534333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypolipidemic effects of CS-500 (ML-236B) in WHHL-rabbit, a heritable animal model for hyperlipidemia.
    Watanabe Y; Ito T; Saeki M; Kuroda M; Tanzawa K; Mochizuki M; Tsujita Y; Arai M
    Atherosclerosis; 1981; 38(1-2):27-31. PubMed ID: 7470202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks.
    Fears R; Richards DH; Ferres H
    Atherosclerosis; 1980 Apr; 35(4):439-49. PubMed ID: 7189661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.
    Yamamoto A; Yamamura T; Yokoyama S; Sudo H; Matsuzawa Y
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):493-7. PubMed ID: 6500769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals.
    Endo A; Tsujita Y; Kuroda M; Tanzawa K
    Biochim Biophys Acta; 1979 Nov; 575(2):266-76. PubMed ID: 508786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study.
    Jones PH; Farmer JA; Cressman MD; McKenney JM; Wright JT; Proctor JD; Berkson DM; Farnham DJ; Wolfson PM; Colfer HT
    Clin Cardiol; 1991 Feb; 14(2):146-51. PubMed ID: 1904333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypercholesterolemia: therapeutic approach].
    Alessandri C; Peverini F
    Clin Ter; 1991 Jun; 137(6):373-97. PubMed ID: 1832610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
    Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
    Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.
    Illingworth DR
    Ann Intern Med; 1984 Nov; 101(5):598-604. PubMed ID: 6567462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
    Tobert JA
    Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Koga T; Shimada Y; Kuroda M; Tsujita Y; Hasegawa K; Yamazaki M
    Biochim Biophys Acta; 1990 Jul; 1045(2):115-20. PubMed ID: 2116173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase.
    Endo A
    J Med Chem; 1985 Apr; 28(4):401-5. PubMed ID: 3981532
    [No Abstract]   [Full Text] [Related]  

  • 19. Homozygous familial hypercholesterolemia: case report of a rare cause of dyslipidemia.
    Alves C; Braid Z
    Pediatr Endocrinol Diabetes Metab; 2011; 17(3):162-5. PubMed ID: 22027071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects.
    Nakaya N; Homma Y; Tamachi H; Shigematsu H; Hata Y; Goto Y
    JAMA; 1987 Jun; 257(22):3088-93. PubMed ID: 3108527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.